Vitality Watch

Dossier pubmed other 01-aug-2026
Doesn't fit the ladder

A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.

Key claim: A calibrated systems pharmacology model of aging predicts that GLP-1 agonist plus SGLT2 inhibitor plus metformin best optimizes metabolic endpoints, whereas GLP-1 agonist plus SGLT2 inhibitor plus rapamycin best optimizes aging-related states, so the two goals do not share the same optimal combination.

Abstract

Aging is a systems-level process linking metabolic dysfunction, inflammation, impaired repair, frailty, and multimorbidity, whereas existing pharmacological strategies usually optimize disease-specific endpoints such as weight loss or HbA1c rather than aging-related trajectories. We developed an SBML-compliant quantitative systems pharmacology (QSP) model in which aging is represented as a dynamic, pharmacologically modifiable endpoint. The model integrates four coupled layers: metabolic/pharmacodynamic responses to GLP-1 receptor agonism, SGLT2 inhibition, metformin and rapamycin; adverse-event dynamics; aging states including damage accumulation, repair capacity, frailty and biological age gap; and biomarker outputs including GDF15, cystatin C, leptin, adiponectin and estimated glucose disposal rate. The semaglutide submodel was calibrated against published STEP trial endpoints, and Bayesian hierarchical meta-analysis, global sensitivity analysis, practical identifiability analysis and internal consistency checks were used to assess model behavior. The calibrated model reproduced semaglutide-associated weight loss, HbA1c reduction and transient nausea within pre-specified error benchmarks. Bayesian meta-analysis confirmed strong metabolic effects for semaglutide, moderate glycaemic effects for SGLT2 inhibitors and metformin, and a near-zero HbA1c effect for rapamycin. Sensitivity analysis revealed largely orthogonal metabolic and aging parameter spaces. Combination simulations identified two mechanistically distinct optima: GLP-1 receptor agonist plus SGLT2 inhibitor plus metformin for metabolic improvement, and GLP-1 receptor agonist plus SGLT2 inhibitor plus rapamycin for aging-related benefit. Metabolic optimisation and aging optimisation are therefore mechanistically distinct objectives that do not converge on the same drug combination. These predictions are hypothesis-generating and require external validation against independent longitudinal datasets and clinical safety evaluation before translation to treatment recommendations.

Why this matters

The trend narrative around AOMs increasingly conflates ‘good for metabolism’ with ‘good for aging,’ and this modeling paper is the first prominent attempt to formally separate those two objectives — predicting that the optimal triple diverges depending on which endpoint you pick. The predictions themselves are in silico (mechanism-plausible) and generate no new human outcome data, but the framing is likely to be picked up by clinics and influencers as if it settled a combination-therapy question it only posed.

Source

Link

Briefing card

A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
Stage: other · pubmed · 01-aug-2026

A calibrated systems pharmacology model of aging predicts that GLP-1 agonist plus SGLT2 inhibitor plus metformin best optimizes metabolic endpoints, whereas GLP-1 agonist plus SGLT2 inhibitor plus rapamycin best optimizes aging-related states, so the two goals do not share the same optimal combination.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1002/psp4.70322

build build 880 · 2bcef25 · 2026-11-18